



PATIENT NAME	Rainz, Winston	ACCESSION	23111500005
PATIENT DOB	July 6, 1982	ORDER CODE	KI23-0000123
PATIENT GENDER	M	SAMPLE TYPE & SOURCE	Tissue
PATIENT PHONE	(542) 395-7861	COLLECTED	10-31-2023, 03:00PM (EDT)
ACCOUNT	Kiyatec Lab	RECEIVED	11-15-2023, 08:23AM (EST)
PROVIDER	Test Provider	REPORTED	11-15-2023, 09:13AM (EST)
REPORT STATUS	FINAL		

TEST INFORMATION	3D Predict Glioma	DIAGNOSIS CODES	C71.3
-------------------------	-------------------	------------------------	-------

QUALITATIVE RESULTS		
	RESULT	FLAG
HIGH GRADE GLIOMA		
Abemaciclib	MODERATE RESPONSE	
Carboplatin	MODERATE RESPONSE	
Dabrafenib	RESPONSE	
Etoposide	NO RESPONSE	
Everolimus	MODERATE RESPONSE	
Irinotecan	NO RESPONSE	
Lomustine	NO RESPONSE	
Osimertinib	NO RESPONSE	
Procarbazine	RESPONSE	
Rucaparib	NO RESPONSE	
Temozolomide	RESPONSE	
Trametinib	NO RESPONSE	

3D Predict Glioma:

Method: Patient tumor tissue is collected, processed, and grown in 3D tissue culture. The cells are exposed to 10 dose variant of 12 drugs. Drug response is determined by calculating the IC50 and prediction has been analytically validated on clinical samples.

3D Predict Glioma:

Stephen Shuford, Lindsay Lipinski, Ajay Abad, Ashley M Smith, Melissa Rayner, Lauren O'Donnell, Jeremy Stuart, Laszlo L Mechtler, Andrew J Fabiano, Jeff Edenfield, Charles Kanos, Stephen Gardner, Philip Hodge, Michael Lynn, Nicholas A Butowski, Seunggu J Han, Navid Redjal, Howland E Crosswell, Cecile Rose T Vibat, Lillia Holmes, Matthew Gevaert, Robert A Fenstermaker, Teresa M DesRochers, Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assay, Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab065, <https://doi.org/10.1093/oaajnl/vdab065>

----- **END OF REPORT** -----